GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geron Corp (STU:GON) » Definitions » Shiller PE Ratio

Geron (STU:GON) Shiller PE Ratio : (As of Dec. 13, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Geron Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Geron Shiller PE Ratio Historical Data

The historical data trend for Geron's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geron Shiller PE Ratio Chart

Geron Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Geron Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Geron's Shiller PE Ratio

For the Biotechnology subindustry, Geron's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Geron's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Geron's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Geron's Shiller PE Ratio falls into.



Geron Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Geron's E10 for the quarter that ended in Sep. 2024 is calculated as:

For example, Geron's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.036/133.0289*133.0289
=-0.036

Current CPI (Sep. 2024) = 133.0289.

Geron Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201412 -0.049 99.070 -0.066
201503 -0.055 99.621 -0.073
201506 -0.053 100.684 -0.070
201509 0.151 100.392 0.200
201512 -0.046 99.792 -0.061
201603 -0.054 100.470 -0.071
201606 -0.045 101.688 -0.059
201609 -0.018 101.861 -0.024
201612 -0.047 101.863 -0.061
201703 -0.047 102.862 -0.061
201706 -0.036 103.349 -0.046
201709 -0.034 104.136 -0.043
201712 -0.042 104.011 -0.054
201803 -0.032 105.290 -0.040
201806 -0.034 106.317 -0.043
201809 -0.026 106.507 -0.032
201812 -0.035 105.998 -0.044
201903 -0.044 107.251 -0.055
201906 -0.071 108.070 -0.087
201909 -0.073 108.329 -0.090
201912 -0.135 108.420 -0.166
202003 -0.072 108.902 -0.088
202006 -0.053 108.767 -0.065
202009 -0.051 109.815 -0.062
202012 -0.058 109.897 -0.070
202103 -0.076 111.754 -0.090
202106 -0.075 114.631 -0.087
202109 -0.068 115.734 -0.078
202112 -0.089 117.630 -0.101
202203 -0.082 121.301 -0.090
202206 -0.066 125.017 -0.070
202209 -0.101 125.227 -0.107
202212 -0.094 125.222 -0.100
202303 -0.065 127.348 -0.068
202306 -0.083 128.729 -0.086
202309 -0.075 129.860 -0.077
202312 -0.083 129.419 -0.085
202403 -0.083 131.776 -0.084
202406 -0.093 132.554 -0.093
202409 -0.036 133.029 -0.036

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Geron  (STU:GON) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Geron Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Geron's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Geron Business Description

Traded in Other Exchanges
Address
919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Geron Headlines

No Headlines